Science Explorer Back to mapMap
Discussion
Company · Tromsø · Norway

Lytix Biopharma (Norway)

lytixbiopharma.comROR OpenAlex
Research works
27
▼ 74% vs 2018-21
Citations
1.1k
42.1 per fractional work
Top-10% rate
20.6%
all institutions 10.0%
Open access
40%
world 40%
International
45%
world 18%
Lytix Biopharma (Norway)

Not ranked overall: Lytix Biopharma (Norway) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Lytix Biopharma (Norway) work in?

In all years, 68% of research at Lytix Biopharma (Norway) is in Life Sciences, 16% in Health Sciences. Its largest fields are Biochemistry, Genetics and Molecular Biology (41%), Immunology and Microbiology (27%), Medicine (15%). It does 3.0× the world's share of Life Sciences.

Life Sciences: 19 fractional works · 68.2% of its workBiochemistry, Genetics and Molecular Biology: 11 fractional works · 41.1% of its workMolecular Biology: 7 fractional works · 26.2% of its workBiotechnology: 3 fractional works · 9.9% of its workGenetics: 1 fractional works · 2.2% of its workMolecular Medicine: 0 fractional works · 1.2% of its workCell Biology: 0 fractional works · 1.0% of its workBiophysics: 0 fractional works · 0.6% of its workImmunology and Microbiology: 7 fractional works · 27.1% of its workMicrobiology: 4 fractional works · 13.3% of its workImmunology: 4 fractional works · 13.1% of its workApplied Microbiology and Biotechnology: 0 fractional works · 0.6% of its workHealth Sciences: 4 fractional works · 15.9% of its workMedicine: 4 fractional works · 15.3% of its workOncology: 2 fractional works · 6.3% of its workSurgery: 1 fractional works · 2.0% of its workInfectious Diseases: 0 fractional works · 1.7% of its workPulmonary and Respiratory Medicine: 0 fractional works · 1.5% of its workRadiology, Nuclear Medicine and Imaging: 0 fractional works · 1.0% of its workOtorhinolaryngology: 0 fractional works · 0.6% of its workPharmacology: 0 fractional works · 0.6% of its workEpidemiology: 0 fractional works · 0.4% of its workGenetics: 0 fractional works · 0.4% of its workPathology and Forensic Medicine: 0 fractional works · 0.4% of its workRheumatology: 0 fractional works · 0.4% of its workHealth Professions: 0 fractional works · 0.3% of its workEmergency Medical Services: 0 fractional works · 0.3% of its workNursing: 0 fractional works · 0.3% of its workNutrition and Dietetics: 0 fractional works · 0.3% of its workPhysical Sciences: 4 fractional works · 15.4% of its workEngineering: 2 fractional works · 6.5% of its workBiomedical Engineering: 2 fractional works · 6.3% of its workSmaller subfields together: 0 fractional works · 0.2% of its workChemistry: 2 fractional works · 6.0% of its workOrganic Chemistry: 1 fractional works · 5.1% of its workSpectroscopy: 0 fractional works · 0.9% of its workComputer Science: 0 fractional works · 1.8% of its workComputational Theory and Mathematics: 0 fractional works · 1.8% of its workMaterials Science: 0 fractional works · 0.4% of its workBiomaterials: 0 fractional works · 0.4% of its workPhysics and Astronomy: 0 fractional works · 0.4% of its workAtomic and Molecular Physics, and Optics: 0 fractional works · 0.4% of its workEnvironmental Science: 0 fractional works · 0.4% of its workSocial Sciences: 0 fractional works · 0.5% of its workEconomics, Econometrics and Finance: 0 fractional works · 0.5% of its workEconomics and Econometrics: 0 fractional works · 0.5% of its workALL ITS WORKLytix Biopharma(Norway)27fractional works, all years
Life Sciences68%Physical Sciences15%Health Sciences16%Social Sciences1%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 12 fields, with their numbers
    1. Biochemistry, Genetics and Molecular Biology1141.1%
    2. Immunology and Microbiology727.1%
    1. Medicine415.3%
    2. Health Professions00.3%
    3. Nursing00.3%
    1. Engineering26.5%
    2. Chemistry26.0%
    3. Computer Science01.8%
    4. Materials Science00.4%
    5. Physics and Astronomy00.4%
    6. Environmental Science00.4%
    1. Economics, Econometrics and Finance00.5%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Who are the top researchers at Lytix Biopharma (Norway)?

Ranked on the quality score, Ketil André Camilio lead among researchers whose main affiliation is Lytix Biopharma (Norway).

  1. 1 Ketil André Camilio Norway · #1,091,441 worldwide 755 citations · 44 works
All ranked researchers at Lytix Biopharma (Norway)

What are the most cited papers from Lytix Biopharma (Norway)?

The most cited paper from Lytix Biopharma (Norway) is "Consensus guidelines for the definition, detection and interpretation of immunogenic cell death" (Lorenzo Galluzzi et al., 2020), with 1,116 citations. Next come "Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)" (216) and "A Synthetic Antimicrobial Peptidomimetic (LTX 109): Stereochemical Impact on Membrane Disruption" (170).

Most cited papers
#PaperReleasedCitations
1 Consensus guidelines for the definition, detection and interpretation of immunogenic cell death Lorenzo Galluzzi et al. · Journal for ImmunoTherapy of Cancer Open access Mar 2020 1,116
2 Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT) Aurélien Marabelle et al. · Annals of Oncology Open access 6 Oct 2018 216
3 A Synthetic Antimicrobial Peptidomimetic (LTX 109): Stereochemical Impact on Membrane Disruption Johan Mattias Isaksson, Bjørn Olav Brandsdal, Magnus Engqvist et al. · Journal of Medicinal Chemistry 6 Jul 2011 170
4 Use of the Capripoxvirus homologue of Vaccinia virus 30kDa RNA polymerase subunit (RPO30) gene as a novel diagnostic and genotyping target: Development of a classical PCR method to differentiate Goat poxvirus from Sheep poxvirus Charles Euloge Lamien, Christian Le Goff, Roland Silber et al. · Veterinary Microbiology 18 Oct 2010 168
5 Synthetic Antimicrobial Peptidomimetics with Therapeutic Potential Bengt Erik Haug, Wenche Stensen, Manar Kalaaji et al. · Journal of Medicinal Chemistry 21 Jun 2008 161
All 61 most cited papers, with filters and sorting

Which keywords describe research at Lytix Biopharma (Norway)?

By fractional works in all years, weighted toward what it does more of than the world: Innate Immunity, Gene Therapy, Immunotherapy, Tumor Targeting, Cancer Immunotherapy, Host Defense, Antimicrobial Peptides and Therapeutic Agents.

▲ more of its work than of the world's◆ about the world's share▼ less than the world's

Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 26 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 26 words, with their numbers
  1. Innate Immunity7▲ 74×4 topics
  2. Gene Therapy5▲ 74×3 topics
  3. Immunotherapy5▲ 29×4 topics
  4. Tumor Targeting4▲ 123×2 topics
  5. Cancer Immunotherapy4▲ 98×3 topics
  6. Host Defense4▲ 210×2 topics
  7. Antimicrobial Peptides4▲ 272×1 topic
  8. Therapeutic Agents4▲ 445×1 topic
  9. Tumor Regression3▲ 142×2 topics
  10. Antigen Presentation3▲ 120×2 topics
  11. Immunity3▲ 34×3 topics
  12. Dendritic Cells3▲ 97×1 topic
  13. Tumor Antigen3▲ 137×1 topic
  14. Arginine Deprivation3▲ 227×1 topic
  15. Bacterial Therapy3▲ 227×1 topic
  16. RNA Interference2▲ 67×1 topic
  17. siRNA Delivery2▲ 100×1 topic
  18. Fluorescence Imaging2▲ 56×1 topic
  19. Nanoparticles2▲ 4.8×2 topics
  20. Photodynamic Therapy2▲ 40×2 topics
  21. Photothermal Therapy2▲ 74×1 topic
  22. Drug Discovery2▲ 15×4 topics
  23. Click Chemistry1▲ 50×1 topic
  24. Copper-Catalyzed Cycloaddition1▲ 120×1 topic
  25. Cyclotides1▲ 216×1 topic
  26. Sortase1▲ 216×1 topic

Which research topics does Lytix Biopharma (Norway) publish most on?

By volume in 2022-now: Immunotherapy and Immune Responses, Cancer Research and Treatments, CAR-T cell therapy research and Antimicrobial Peptides and Activities.

Immunotherapy and Immune Responses: 0 fractional worksCancer Research and Treatments: 0 fractional worksCAR-T cell therapy resea…0CAR-T cell therapy research: 0 fractional worksAntimicrobial Peptides a…0Antimicrobial Peptides and Activities: 0 fractional worksRNA Interference and Gen…0RNA Interference and Gene Delivery: 0 fractional worksCancer Immunotherapy and Biomarkers: 0 fractional worksRadiomics and Machine Learning in Medical Imaging: 0 fractional worksSarcoma Diagnosis and Treatment: 0 fractional worksEconomic and Financial Impacts of Cancer: 0 fractional worksLung Cancer Diagnosis and Treatment: 0 fractional works
ImmunologyBiotechnologyOncologyMicrobiology4 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Immunotherapy and Immune Responses Immunology 0 works
  2. 2 Cancer Research and Treatments Biotechnology 0 works
  3. 3 CAR-T cell therapy research Oncology 0 works
  4. 4 Antimicrobial Peptides and Activities Microbiology 0 works
  5. 5 RNA Interference and Gene Delivery Molecular Biology 0 works
  6. 6 Cancer Immunotherapy and Biomarkers Oncology 0 works
  7. 7 Radiomics and Machine Learning in Medical Imaging Radiology, Nuclear Medicine and Imaging 0 works
  8. 8 Sarcoma Diagnosis and Treatment Pulmonary and Respiratory Medicine 0 works
  9. 9 Economic and Financial Impacts of Cancer Economics and Econometrics 0 works
  10. 10 Lung Cancer Diagnosis and Treatment Pulmonary and Respiratory Medicine 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available40.0%not open60.0%

World: 40% of research is openly available.

with international co-authors44.9%domestic only55.1%

World: 18% is written across borders.

How has Lytix Biopharma (Norway)'s research output changed?

Output in 2022-2025 was 74% lower than in 2018-2021.

still counting20052010201520202025
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Lytix Biopharma (Norway) as a percentage of every work published that year, 0.0000083% in 2024.

still counting0.000050%0.00010%Lytix Biopharma (Norway)0.0000029% in 202520102020

Fractional works of Lytix Biopharma (Norway) over all fractional works that year. How the balance of science has shifted.

Other research institutions in Tromsø

All research institutions in Tromsø

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Lytix Biopharma (Norway). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.